-
Article
Cumulative incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage I seminoma treated with a risk-adapted strategy: a Spanish single-centre retrospective analysis
To describe the incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage 1 seminoma (S1S) testicular cancer (TC) treated with a risk-adapted strategy.
-
Article
Open AccessExploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial
Post hoc analysis of the JAVELIN Bladder 100 trial of avelumab maintenance in locally advanced/metastatic urothelial carcinoma (la/mUC) to determine the interaction by programmed death ligand 1 (PD-L1) status ...
-
Article
Challenges of diagnosing homologous recombination deficiencies in metastatic prostate cancer: a six-year experience from a single institution
We evaluated the prevalence of homologous recombination deficiencies (HRD) to determine the efficacy of different techniques and clinical characteristics of patients.
-
Article
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
Single-agent PD-1/PD-L1 inhibitors have shown limited efficacy in unselected mCRPC. The evidence of a survival benefit with sipuleucel-T and ipilimumab, provides a rationale to study further increasing immunog...
-
Article
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer
Durvalumab is a programmed death-ligand 1 (PD-L1) inhibitor with clinical activity in advanced urothelial cancer (AUC)1. AUC is characterized by several recurrent targetable genomic alterations2–5. This study ( ...
-
Article
Open AccessReal-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry
Despite standard-of-care androgen-deprivation therapy and an increasing number of treatment options, the mortality rate for prostate cancer remains high. Progress to metastatic castration-resistant prostate ca...
-
Article
Open AccessReal-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry
Metastatic prostate cancer has a 30% 5-year survival rate despite recent therapeutic advances. There is a need to improve the clinical understanding and treatment of this disease, particularly in the real-worl...
-
Article
Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations
The availability of agents targeting the vascular endothelial growth factor or mammalian target of rapamycin [mTOR] pathways has provided new treatment options for patients with metastatic renal cell carcinoma...
-
Article
Open AccessControversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature
More than 429,000 patients worldwide are diagnosed with bladder cancer each year and muscle-invasive bladder cancer has an especially poor outcome. The median age at diagnosis is over 70 years, and many patien...
-
Article
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma
Clear-cell renal cell carcinoma (RCC) is the most common kidney cancer. New treatment options of localized RCC recently incorporated include laparoscopic surgery, nephron-sparing surgery, ablative techniques ...
-
Article
Castration-resistant metastatic prostate cancer: current status and treatment possibilities
Prostate cancer (PCa) is the most common cancer in the male population in Western countries, second to skin cancer. Hormonal therapy allows long-lasting and effective control of cancer-related symptoms in adva...
-
Article
Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain
Sunitinib, an oral, multitargeted receptor tyrosine kinase inhibitor, delays disease progression, with a median overall survival (OS) of more than 2 years, improves quality of life and is becoming the first-li...
-
Article
Current management of muscle-invasive bladder cancer
Management of muscle-invasive bladder cancer (MIBC) has changed little in the last twenty years. The gold standard treatment is still cystectomy, but it has a significant negative impact on quality of life. Bl...
-
Article
SEOM guidelines: non-seminomatous germ cell cancer (NSGCC)
Non-seminomatous germ cell cancer (NSGCC) is a curable disease; its treatment has not essentially changed since the 1980s. BEP (bleomycin, etoposide, cisplatin) chemotherapy remains the standard of care. NSGCC...
-
Article
Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma
The speed at which targeted therapies are being developed and incorporated into the treatment of advanced renal cell carcinoma (RCC) is surprising. After decades in which the only systemic treatment options av...
-
Article
Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations
Elderly or frail patients are often excluded from clinical trials. As a result, clinical outcome of these patients may differ from those obtained in trials. This situation may also hold true for patients who h...
-
Article
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer
For almost the last two decades, interleukin-2 and interferon-α have been the only systemic treatment options available for metastatic renal cell carcinoma. However, in recent years, five new targeted therapie...
-
Article
Disseminated retroperitoneal choriocarcinoma with open fistula to intestine. «Restitutio ad integrum» with chemotherapy alone
We hereby present a clinical case of a germinal tumour with a pulmonary and retroperitoneal dissemination in form of a great adenopathic mass that fistulizes into the duodenum, that obtained a complete resolut...
-
Article
Anemia hemolítica microangiopática y metástasis cardíaca por carcinoma de cabeza y cuello
Microangiopathic haemolytic anemia (MAHA) complicates occasionally clinical evolution of disseminated tumors, usually adenocarcinoma-type, but is association with a squamous cell cancer of head and neck origin...
